Spots Global Cancer Trial Database for Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
Official Title: Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) Previously Treated With Imatinib
Study ID: NCT01110668
Conditions
Interventions
Study Description
Brief Summary: This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Adana, , Turkey
Novartis Investigative Site, Ankara, , Turkey
Novartis Investigative Site, Istanbul, , Turkey
Novartis Investigative Site, Izmir, , Turkey
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
